Leonardo Alonso, MD
Psychiatry · Miami, FLNPI 1588620470
Payments from drug & device makers
Across 729 payments — averaging $2285.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$465K
- Janssen Research & Development, LLC$370K
- AbbVie$278K
- Avanir Pharmaceuticals, Inc.$221K
- Acadia Pharmaceuticals Inc$129K
- Biohaven Pharmaceutical Holding Company Ltd.$57K
- plus $146K from 23 others
Across 18 payments — averaging $2281.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$38K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$3K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 16 | $465,004 |
| Janssen Research & Development, LLC | 38 | $370,095 |
| AbbVie(2 entities) | 193 | $278,146 |
| Avanir Pharmaceuticals, Inc. | 15 | $220,808 |
| Acadia Pharmaceuticals Inc | 26 | $128,687 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $56,970 |
| Sumitomo Pharma America, Inc. | 47 | $27,347 |
| E.r. Squibb & Sons, L.L.C. | 7 | $24,426 |
| Livanova USA, Inc. | 14 | $22,697 |
| Sage Therapeutics, LLC | 6 | $18,683 |
| UCB SA | 2 | $17,000 |
| Novo Nordisk AS | 4 | $16,700 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 29 | $12,818 |
| Lundbeck LLC | 70 | $1,292 |
| Otsuka America Pharmaceutical, Inc. | 52 | $1,092 |
| Neurocrine Biosciences, Inc. | 46 | $983 |
| Takeda Pharmaceuticals U.S.A., Inc. | 53 | $935 |
| Teva Pharmaceuticals USA, Inc. | 20 | $683 |
| Axsome Therapeutics, Inc. | 27 | $576 |
| Vanda Pharmaceuticals Inc. | 11 | $263 |
| Johnson & Johnson | 7 | $249 |
| Sunovion Pharmaceuticals Inc. | 17 | $204 |
| Bausch Health US, LLC | 7 | $143 |
| Tris Pharma Inc | 6 | $121 |
| Eisai Inc. | 1 | $100 |
| Alkermes, Inc. | 5 | $83 |
| Supernus Pharmaceuticals, Inc. | 3 | $47 |
| Noven Therapeutics, LLC | 1 | $23 |
| TMS Neurohealth Centers Inc. | 1 | $17 |
How this compares
$1,666,193 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatry in Miami
- Silvia Silva-DulucMiami$11.7M
- Patricia JunqueraMiami$10.8M
- Evelio SosaMiami$6.9M
- Mario CuervoMiami$6.7M
- Emelina ArochaMiami$4.9M
- Maria RodilMiami$4.5M
- Marc AgroninMiami$4M
- Nancy Navarro-GonzalezMiami$2.6M
- Francisco RicartMiami$2.6M
- Durim BozhdarajMiami$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.